When a person is infected with malaria by the bite of a mosquito, sporozoites travel through the bloodstream and enter hepatocytes. The parasite develops within the liver cell for days to weeks, and during this period there are no symptoms. Only after the liver stage parasites mature, and merozoites are released to invade red blood cells, do the fevers, chills and lethal complications of malaria begin. Thus, a vaccine aimed at sporozoites or liver stage parasites could eliminate malaria infections before clinical disease appears.
When a person is infected with malaria by the bite of a mosquito, sporozoites travel through the bloodstream and enter hepatocytes. The parasite develops within the liver cell for days to weeks, and during this period there are no symptoms. Only after the liver stage parasites mature, and merozoites are released to invade red blood cells, do the fevers, chills and lethal complications of malaria begin. Thus, a vaccine aimed at sporozoites or liver stage parasites could eliminate malaria infections before clinical disease appears.
Immunization with radiation-attenuated sporozoites can protect rodents and humans against live sporozoite challenge (1, 2). One hypothesis is that this protective immunity is mediated by cytotoxic T cells directed against malaria antigens on the infected hepatocyte . Several recently published experiments give support to this idea. Immune animals became susceptible to sporozoite infection if they were depleted of their CD8+ T cells (3, 4) , but the antigens recognized by these cells and their site and mode of action were not determined. Infiltrates with CD8+ and CD4' T cells and other cellular elements were found in the livers of immune animals after challenge with sporozoites and these infiltrates formed after the transfer of immune CD8 + cells (5) . Unfractionated spleen cells from immune animals eliminated malaria-infected hepatocytes from in vitro culture (5) , but the active cell types and the targeted parasite antigens were not identified . A very recent study showed that mice were protected by adoptive transfer of cloned CD8+ T cells specific for an epitope on the Plasmodium berghei circumsporozoite (CS) 1 protein (6). However, it was not shown that these cells were attacking infected hepatocytes directly, or releasing
Materials and Methods
Mice. 6-wk-old BALB/cByj and B10 .D2 female mice were purchased from The Jackson Laboratories, Bar Harbor, ME . BALB.K mice were obtained from Biocon, Rockville, MD.
Parasites. Clone 1 .1 of P. yoelii 17X (NL) was grown in Anopheles stephensi mosquitos and harvested as previously described (4) . For some control experiments P. berghei ANKA clone sporozoites were similarly grown and harvested .
Immunization Protocol. Dissected sporozoites received 12,000 Rad of 'y radiation from a Cesium-137 source. Mice were given sporozoite immunizations through the tail vein at 2-4-wk intervals . Either of two immunization schedules was used : two doses of 60,000 and 50,000 sporozoites, or three doses of 75,000, 25,000, and 25,000 sporozoites . BALB/c mice were protected against sporozoite challenge by either protocol .
Cell Culture. Spleens were removed from animals 2-12 wk after their last sporozoite immunization . 5 x 10 6 spleen cells were aliquoted into 2 ml of medium in wells of a 24-well tissue culture plate . Medium was RPMI 1640 supplemented with 10% FCS, L-glutamine, 50 U/ml each of penicillin and streptomycin, and 2-ME at 5 x 10 -5 M . Peptide antigens were added at 5 fM concentrations, and cultures were incubated for 2 d at 37°C, 5% C02 . At that time, 0 .2 ml of rat Con A culture supernatant (RCAS) (Collaborative Research Inc ., Bedford, MA) was added to each well, and cultures were reincubated for an additional 5 d.
Peptides. Using the method of Houghten (7), peptides were synthesized corresponding to amino acid sequences from the P. yoelii CS protein (8) . Peptides were not desalted before use and were not toxic to target cells or cell cultures at concentrations below 60 'M . They were checked for purity by HPLC analysis. The 26 peptides used for initial screening spanned the entire protein, each peptide being 20 amino acids long and overlapping its neighbors by 10 amino acids (Fig. 1) . For finer analysis of the CTL epitope, a nested set of peptides was synthesized by progressively shortening the amino acid sequence 280-296 at both NH2 and COOH ends .
Monoclonal Antibodies. Anti-CD8 mAb 2 .43 (9) was used for in vitro complement lysis . For detection of liver stage schizonts, mAbs NYLS1 and NBSI were developed and kindly provided by Dr. Yupin Charoenvit (Naval Medical Research Institute, Bethesda, MD) .
Target Cells. Mouse tumor cell lines P815 (H-2d) and EL4 (H-2b) were purchased from American Type Culture Collection, Rockville, MD. 18 h before use as targets, 10 6 cells were placed in 2 ml of medium in single wells of a 24-well tissue culture plate . To this was added 0 .1 MCi of 5 'Cr as a sterile sodium-chromate solution (Dupont-New England Nuclear, Inc., Boston, MA) and synthetic peptide at the desired concentration . These cells were incubated overnight at 37°C, 5% C02 . In the morning they were washed twice, recultured in 1 ml of medium for 1 h at 37°C, washed twice again, and counted for use as target cells . For some experiments, peptide was not added the night before, but only during the chromium-release assay.
Chromium-release Assay. 5,000 target cells were placed in well of a 96-well U-bottomed plate . Effector cells and synthetic peptide were added at the desired concentrations . For lysis of CD8' cells, effector cells were incubated for 1 h at 37°C with mAb 2 .43 and rabbit complement (Accurate Scientific, Westbury, NY) . Normal rat serum Ig and complement were used as control . Total volume was 0 .2 ml, and experimental wells were reproduced in triplicate . Plates were centrifuged at 500 g for 2 min, and incubated for 6 h at 37°C, 5 1 70 C02 . At that time supernatants were harvested using the Skatron SCS system (Skatron, Inc., Sterling, VA), and released "Cr was detected by scintillation counting . Maximum release was determined by lysing target cells with 10% SDS . Spontaneous release of "Cr was -20% of maximum release . Calculation of percent specific lysis = [(experimental release -spontaneous release)/(maximum release -spontaneous release)] x 100 . Calculation of percent peptide specific lysis = (percent specific lysis oftargets with peptide) -(percent specific lysis oftargets without peptide).
In Vitro Killing of Plasmodium-infected Hepatocytes. Mouse hepatocytes were prepared using enzymatic perfusion (10, 11) . The hepatocyte preparations used in screening cultures were depleted of Kupffer cells and macrophages by differential centrifugation and by cultivation in medium containing 7 x 10-5 M hydrocortisone hemisuccinate . 105 hepatocytes were seeded in eight-chamber plastic Lab-tek slides (Miles Research, Elkhart, IN) in MEM supplemented with 10% FCS and allowed to attach overnight at 37°C, 5% C02 . After removal of medium from the culture chambers, 5 x 104 sporozoites were added in 50 j1 of fresh medium . 3 h after inoculation, medium containing the suspended sporozoites was removed and replaced by 300,ul offresh medium, and cultures were incubated for another 24 h. Medium was then replaced by medium containing the required number ofcultured lymphocytes and incubated overnight. Experimental wells were repeated in triplicate . Cultures were then examined by an immunofluorescence assay to determine the numbers ofsporozoites developing into schizonts (12) . P. yoelii schizonts were detected using mAb NYLS1 specific for liver stage schizonts, and P. berghei schizonts were detected using mAb NBS1 specific for P. berghei CS protein. Inhibition was calculated by a pairwise comparison ofkilling by identically cultured spleen cells from sporozoite immunized and normal mice. Percent inhibition = [1 -(number of schizonts with lymphocytes cultured from immunized mice/number of schizonts with lymphocytes cultured from normal mice)] x 100 .
Results
To look for CTL epitopes on the P. yoelii CS protein, we synthesized 26 peptides that spanned the molecule (Fig. 1) . We pooled these peptides into five groups, (1-6, 7-11, 12-16, 17-21, 22-26) and cultured spleen cells from sporozoite-immunized mice with these pools and RCAS as a source of IL-2. After 7 d viable cells from these cultures were used as effector cells in an in vitro cytotoxicity assay. The target cells were "Cr-labeled syngeneic tumor cells pulsed with a single 1 of the 26 peptides . Spleen cells that had been cultured with each peptide pool were then added to targets pulsed with individual peptides from that pool. Peptide 19 (281-300), and to a lesser degree peptide 18 (271-290), could sensitize target cells for lysis (Fig. 2) .
When immune spleen cells from BALB/c mice were cultured with peptide 18 alone, no CTL activity could be seen (data not shown). However cultures with peptide 19 as stimulating antigen produced CTL activity (Fig. 3) . Both peptide 19 and RCAS were necessary to generate this activity, which was MHC restricted, as peptide-pulsed EL-4 cells (H-2b) were not lysed (Fig. 3, Exp . 1 ). Another strain of mice also carrying the H-2d alleles, B10.D2, also made CTL against peptide 19 when immunized with P. yoelii sporozoites (data not shown). Spleen cells from unimmunized BALB/c mice would not produce CTL when cultured with peptide 19 (Fig. 3 To further define this CTL epitope, we synthesized a nested set of peptides by deleting single amino acids from the NH2 and COOH ends of the P . yoelii CS 280-300 sequence . Immune spleen cells cultured with peptide 19 (281-300) were then tested against tumor targets pulsed with the nested peptides at various concentrations (Fig. 5) . Shortening or lengthening by a single NH2-terminal amino acid reduced target cell labeling, and shortening by two amino acids abolished all lysis. At the COOH terminus, truncated peptides had full activity until the isoleucine at position 296 was removed. Complete loss of target sensitization occurred with Spleen cells from sporozoite immunized BALB/c mice were cultured with peptide 19 (amino acids 281-300) and then tested in a CTL assay against targets in the presence of each of the nested peptides at several concentrations.
deletion of the lysine at position 294. Thus a 13-amino acid core seems to be essential for sensitization but optimal activity requires a peptide containing one additional N112-terminal, and two additional C0011-terminal residues (Fig. 4) . We have named this 16-amino acid sequence PYCTLI. Although infected hepatocytes can be killed by immune T cells (5) , no malaria antigens, including the CS protein, had been previously identified on the surface of infected liver cells. We wished to know ifPYCTLI was a target antigen on malariainfected hepatocytes. Mouse hepatocytes were cultured in monolayers and infected with P. yoelii sporozoites (5, 10-12) . 24 h later spleen cell cultures from sporozoiteimmunized or normal mice stimulated with PYCTLI or a control (peptide 15) were added and allowed to remain overnight . The hepatocyte cultures were then fixed and stained, and the number of liver stage malaria parasites was counted. Spleen cell cultures stimulated with PYCTLI substantially decreased the number of liver stage parasites present in the cultures (Fig. 6 ). This effect was not seen when control peptide was used to stimulate cultures ofimmune spleen cells. Antiparasitic activity was MHC restricted, as parasites grown in BALB .K liver cells were not affected (Fig.  6) . The effector cells were also antigen specific, as P. bergthei liver stage parasites were not killed .
Discussion
These data demonstrate that PYCTLI, a 16-amino acid fragment from the P. yoelii CS protein, is a biologically significant epitope recognized by CTL on infected liver cells. Immunization with irradiated sporozoites induces CD8+ , MHC-restricted CTL to PYCTLI, and specific, MHC-restricted CTL to this peptide eliminate parasites from hepatocyte culture. PYCTLI is thus the first known malaria antigen presented on the surface of infected hepatocytes. It may derive from CS protein sloughed into the liver cell cytoplasm during sporozoite invasion (14-16), or represent material passing through the parasitophorous vacuole. In either case, our data show that PYCTLI is presented with class I molecules on the hepatocyte surface. B&INc P.yoehi PYCTLI " BalWc P. yoelii Control O Bell P. yoelii PYCTLI Bab.K P.yoelu Control " BNWc P.berghei PYCTL1 O Belb/c P. berghei Control FIGURE 6. Inhibition of parasite growth in hepatocytes. Hepatocytes from BALB/c (H-2d) or BALB .K (H2k) mice were cultured in monolayers, infected with P. yoelii or P. berghei ANKA sporozoites, and incubated for 24 h. At that time, spleen cells from normal BALB/c or P. yoelii sporozoite immunized BALB/c mice cultured with either PYCTLI or peptide 15 (control) were added to the infected hepatocytes at several concentrations . 24 h later the hepatocyte monolayers were fixed and stained, and the numbers of liver stage parasites was counted . Numbers of parasites in cultures with immune and normal spleen cells were compared, and percentinhibition was calculated . Negative inhibition is marked as zero. PYCTLI appears to be the only class I-restricted CTL epitope on the P. yoelii CS protein recognized by sporozoite-immunized H-2d mice . We have mapped a 13-amino acid minimal core required for sensitization of targets for lysis, and 3 adjacent amino acids that enhance activity to maximal levels . In our initial screening experiments, a 20-amino acid peptide (281-300) containing this epitope was the most effective of all peptides at sensitizing targets for lysis. This peptide containing PYCTLI was able to stimulate immune cells to become CTL in vitro, as well as to sensitize targets for lysis by these cells. The neighboring peptide (271-290), containing 10 of the 13 core amino acids of PYCTLI, had some reduced ability to label targets in some experiments, but was unable to stimulate immune cells to have cytotoxic activity. Therefore, we do not believe that this activity in peptide 271-290 of the P. yoelii CS represents a separate epitope in BALB/c mice .
Synthetic peptides provided an easy means of defining this CTL epitope. There are two complementary strategies for using peptides to find T cell epitopes . The first is to synthesize peptides chosen by predictive algorithms (17, 18) . PYCTLI was predicted to fold as an amphipathic a-helix, and was a T epitope candidate on that basis. The second strategy is to empirically produce peptides that are screened for reactivity with T cells. Typically, it is not practical to synthesize all possible peptides, and overlapping peptides are used. This works well if T cell epitopes are as short as eight or nine amino acids, but screening is difficult for longer T cell epitopes. Our series ofoverlapping peptides, 20 amino acids long overlapping by 10, reproduces all possible sequences of 11 amino acids or shorter. However, we are missing 10% of all possible 12-amino acid sequences, and 20% of all 13-amino acid sequences . Our core sequence of PYCTLI has 13 amino acids, and 16 amino acids are necessary for optimal activity. By these calculations there is a small chance that another long H-2d-restricted CTL epitope might exist on the P. yoelii CS protein, but this seems unlikely as most T cell epitopes are shorter than 13 amino acids .
PYCTLI is distinct from, but overlaps by nine amino acids, the recently described CTL epitope 249-260 on the P. berghei CS protein (NDDSYIPSAEKI) (6) . Four ofour experiments illustrate their differences. First, the P. berghei peptide corresponding to PYCTLI (Fig. 4) cannot sensitize targets for killing by CTL to PYCTLI. Second, epitope mapping experiments using nested peptides (Fig. 5) show that the four COOHterminal amino acids of PYCTLI are required for activity. These four are absent from the P. berghei epitope. Also, addition of NH2-terminal amino acids to PYCTLI decreases its ability to sensitize targets, although lengthening increases its overlap with the P. berghei epitope. Third, spleen cells from BALB/c mice immunized with P. berghei sporozoites could not be stimulated to make CTL to PYCTLI. Lastly, P. berghei infected hepatocytes were not killed by PYCTLI reactive cultures that did kill P.yoelii liver stage parasites. We conclude that P. yoelii and P. bergheicontain different epitopes mapping to a small region of the CS molecule.
This region, adjacent to the NH2 terminal of constant region II, may be a center for T cell reactivity on all CS proteins . It is the site of TH2R, a dominant CD4 T cell epitope on the P. falciparum CS protein (19) . In P. yoelii, P. berghei, and P. falciparum this region has the amino acid sequence consistent with folding as an amphipathic a-helix (17) . This may reflect a structural requirement for the normal function of the CS protein on sporozoites, which incidently makes it a conspicuous target antigen for T cells. In P. falciparum, naturally occurring variation at the Th2R site shows the importance of selective pressure directed at this region (20) . Interestingly, these variant sequences ofTH2R can still be recognized by T cells ofdifferent specificity (21) . The parasite appears unable to modify this part of the protein sufficiently to destroy the structure recognized by T cells.
A vaccine that induced CTL to the CS protein might be expected to protect mice against malaria by killing infected liver cells. However, there may be many obstacles to this approach . Although CTL to PYCTL1 are induced by irradiated sporozoites and are active against infected hepatocytes, it is quite possible that other non-CS proteins in P. yoelii have CTL epitopes that are more prominent in the protective immune response. We cannot be sure from these studies whether PYCTLI is a major player in immunity to sporozoite challenge. We have found that although both BALB/c (H-2d) and 1310.132 (H-2d) mice make CTL against PYCTL1 when immunized with P, yoelii sporozoites, only the BALB/c mice are solidly protected against sporozoite challenge (22) . Also, both recombinant Salmonella and pseudorabies virus containing the P. yoelii CS gene, successfully induced CTL to PYCTLI in BALB/c mice but the animals were not protected against infection by sporozoites (Flynn, J., W. R. Weiss, K. A. Norris, H. S. Seifert, S. Kumar, and M . So, manuscript in preparation). The CS protein may be a more important antigen in P. berghei. Recombinant Salmonella containing the P. berghei CS can partially protect mice against P. berghei sporozoites (23) . As mentioned previously, CTL clones to the P. berghei CS can also protect mice (6) . We conclude that the CS protein is a more significant antigen quantitatively or qualitatively in some malarias than in others . What determines this remains unknown, as does its role in immunity to the human malarias.
Other difficulties cloud the path toward CTL-based vaccines against malaria. We have found only a single CTL epitope recognized by H-2d mice on the P. yoelii CS protein. Similarly, H-2d mice recognize only one CTL epitope on the P. berghei CS protein (6). The P. falciparum CS protein contains a single CTL epitope seen by H-2k mice and no CTL epitopes seen by H-2d mice (24) . This paucity of CTL epitopes has also been seen when other proteins have been analyzed (25) (26) (27) , but it is not understood why they are so much less frequent than T helper epitopes . An ideal CTL vaccine would contain multiple parasite CTL epitopes, which will probably need to be drawn from many parasite antigens which are at this point undefined. This multiplicity would circumvent the lack of presentation by certain MHC alleles, and parasite variation ofT cell epitopes (20) . Immunization with P. berghei-irradiated sporozoites protects all strains ofmice, indicating that many such antigens may exist (28) . However, in the case of P. yoelii, even immunization with the whole irradiated sporozoite only protects a few strains of congenic mice (22) . If the human malarias behave as P. yoelii instead of P. berghei, any vaccine may have to do better than the whole radiation-attenuated parasite to overcome genetic low responsiveness to malaria antigens .
Some answers to these problems are on the horizon. T helper epitopes have been found that are recognized by a large number of MHC alleles (29) , and it is possible that widely reactive CTL epitopes may exist as well . In addition, there is much work currently aimed at defining other target antigens on infected liver cells besides the CS protein (30, 31) . It is our hope that the addition of these factors to T epitopes from the CS protein will result in a vaccine that will overcome the limitations of genetic control and parasite variation . Summary Irradiated malaria sporozoites can induce CD8 + T cells that are required for protection against infection . However, the parasite antigens targeted by this immune response are unknown . We have discovered a 16-amino acid epitope from the Plasmodium yoelii circumsporozoite (CS) protein that is recognized by cytotoxic T cells from immune mice. Lymphocytes stimulated with this peptide can kill P . yoelii liver stage parasites in vitro in an MHC-restricted, antigen-specific manner. Thus, epitopes from the CS protein are presented on the surface of infected hepatocytes and can be targets for T cells, even though intact CS protein has not been detected on the surface of the infected hepatocyte. A vaccine that induced CTL to parasite antigens might protect humans against malaria by eliminating liver stage parasites.
